BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
latest_posts
- 1
The Magnificence of Extraordinariness: Presenting Valuable Adornments and Gemstones - 2How to watch ‘The Traitors’ U.K. Season 4 premiere today from the U.S.
- 3Top 10 Moving Style Architects of the Year
- 4In the stomach of a mummified wolf pup, scientists find DNA from a woolly rhinoceros
- 5Scientists Just Discovered Japan’s First New Bird Species in Over 40 Years
- Instructions to Grasp the Innovation Behind 5G Pinnacles\
- Beating Wellbeing Difficulties: Individual Victories in Health
- Figure out How to Streamline Your Profits in Gold Speculation
- Mont Blanc road tunnel reopens to traffic after 15 weeks of repairs
- The teen queen bee of 'Laguna Beach' is now a 'cringey' mom
- Why the UAE has incurred the wrath of Somalia
- See the 'amazing' photos of Earth taken on historic Artemis II moon mission
- Comet C/2025 K1 (ATLAS) breaks apart in incredible telescope photos
- Doctor's orders: Eat ice cream, and other tips for a long and healthy life
